Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H23N3O2 |
| Molecular Weight | 313.3941 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H]1CCCN1CCCOC2=CC=C(C=C2)C3=NNC(=O)C=C3
InChI
InChIKey=XUKROCVZGZNGSI-CQSZACIVSA-N
InChI=1S/C18H23N3O2/c1-14-4-2-11-21(14)12-3-13-23-16-7-5-15(6-8-16)17-9-10-18(22)20-19-17/h5-10,14H,2-4,11-13H2,1H3,(H,20,22)/t14-/m1/s1
| Molecular Formula | C18H23N3O2 |
| Molecular Weight | 313.3941 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
CNS Activity
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Discovery and characterization of 6-{4-[3-(R)-2-methylpyrrolidin-1-yl)propoxy]phenyl}-2H-pyridazin-3-one (CEP-26401, irdabisant): a potent, selective histamine H3 receptor inverse agonist. | 2011 Jul 14 |
|
| Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. | 2016 Oct |
Patents
Sample Use Guides
Irdabisant had high affinity for both human (Ki=2.0 nM) and rat (Ki=7.2 nM) histamine H3 receptor with greater than 1000-fold selectivity over the human histamine H1 receptor, histamine H2 receptor, and histamine H4 receptor subtypes and against an in vitro panel of 418 G-protein-coupled receptors, ion channels, transporters, and enzymes.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:01:22 UTC 2023
by
admin
on
Fri Dec 15 16:01:22 UTC 2023
|
| Record UNII |
WH7ISP34KA
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
XX-146
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
DTXSID50143375
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
C170078
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
DB12900
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
WH7ISP34KA
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
9470
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
300000018053
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
25070031
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
1005402-19-6
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY | |||
|
CHEMBL1829335
Created by
admin on Fri Dec 15 16:01:22 UTC 2023 , Edited by admin on Fri Dec 15 16:01:22 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
